Abstract ND06: ABBV-CLS-484: An active site PTPN2/N1 inhibitor that augments the immune response and sensitizes tumors to immune-mediated killing
Christina K. Baumgartner(AbbVie (United States)), Philip R. Kym(AbbVie (United States)), Marcia N. Paddock(California State University, San Marcos), Kelly L. Klinge(AbbVie (United States)), Jennifer M. Frost(Mount Sinai Hospital), Kyle Halliwill(AbbVie (United States)), Clay Beauregard, Elliot P. Farney(AbbVie (United States)), Kathleen A. McGuire(AbbVie (United States)), Jaqueline Aguado(AbbVie (United States)), Keith M. Hamel(AbbVie (United States)), Kathleen B. Yates(Broad Institute), Robert T. Manguso(Broad Institute), Zhaoming Xiong(AbbVie (United States)), Marinka Bulic(AbbVie (United States)), Liang Mu(AbbVie (United States)), Prasanthi Geda
Cited by 7
Related Papers
CD39 Expression Identifies Terminally Exhausted CD8+ T Cells
|PLoS Pathogens|2015|390
An expanded universe of cancer targets
|Cell|2021|221
Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug Conjugates
|Journal of the American Chemical Society|2016|141